Key terms

About DNA

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DNA news

Apr 14 9:40pm ET Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA) Apr 11 7:02am ET Ginkgo Bioworks acquires AgBiome’s platform assets, terms not disclosed Apr 08 7:11am ET Ginkgo Bioworks, IdeeLab Biotechnology enter agreement Apr 03 7:07am ET Ginkgo Bioworks, Prozomix announce new partnership Apr 02 7:10am ET Ginkgo Bioworks acquires Modulus Therapeutics’ cell therapy platform assets Mar 28 8:46am ET Largest borrow rate increases among liquid names Mar 28 7:05am ET Ginkgo Bioworks awarded $6M contract from DARPA Mar 27 7:03am ET Ginkgo Bioworks and AQUA Cultured Food announce partnership Mar 20 8:46am ET Largest borrow rate increases among liquid names Mar 19 8:45am ET Largest borrow rate increases among liquid names Mar 13 5:35am ET ProteoNic Biosciences announces pact with Ginkgo Bioworks Mar 12 8:45am ET Largest borrow rate increases among liquid names Mar 12 7:18am ET Ginkgo Bioworks, CDC, Xwell expand Traveler-based Genomic Surveillance program Mar 05 3:11am ET Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV) Mar 04 8:05pm ET Cathie Wood’s ARK Investment bought 5.8M shares of Ginkgo Bioworks today Mar 01 7:07am ET Ginkgo Bioworks price target lowered to $3 from $7 at TD Cowen Feb 29 11:45pm ET Buy Rating Affirmed for Ginkgo Bioworks Amidst Strategic Growth and Diversification Feb 29 5:03pm ET Ginkgo Bioworks sees FY24 revenue $215M-$235M, consensus $279.55M Feb 29 5:02pm ET Ginkgo Bioworks reports Q4 EPS (11c), consensus (10c) Feb 29 2:49pm ET Ginkgo Bioworks options imply 16.0% move in share price post-earnings Feb 28 7:18am ET Ginkgo Bioworks acquires Proof Diagnostics, no terms disclosed Feb 28 7:17am ET Ginkgo Bioworks acquires Patch Biosciences, no terms disclosed Feb 28 7:16am ET Ginkgo Bioworks acquires key assets of Reverie Labs, no terms Feb 22 8:04pm ET Cathie Wood’s ARK Investment bought 2.46M shares of Ginkgo Bioworks today Feb 15 7:19am ET Ginkgo Bioworks and Agenus subsidiary awarded MCDC vaccine contract Jan 25 8:26pm ET Cathie Wood’s ARK Investment bought 711K shares of Ginkgo Bioworks today Jan 24 8:07pm ET Cathie Wood’s ARK Investment bought 511K shares of Ginkgo Bioworks today Jan 23 8:05pm ET Cathie Wood’s ARK Investment bought 119K shares of Ginkgo Bioworks today Jan 18 9:26pm ET Cathie Wood’s ARK Investment bought 129K shares of Ginkgo Bioworks today Jan 17 8:08pm ET Cathie Wood’s ARK Investment bought 886K shares of Ginkgo Bioworks today Jan 15 7:36pm ET Concentric by Ginkgo enters into co-marketing agreement with Illumina

DNA Financials

1-year income & revenue

Key terms

DNA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DNA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms